Publications

CAR-T

Publications

Follicle-stimulating Hormone Receptor is Expressed by Most Ovarian Cancer Subtypes and is a Safe and Effective Immunotherapeutic Target

Breast Cancer Vaccine

Publications

Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer

Ovarian Cancer Vaccine

Publications

Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Mullerian Hormone Receptor II

Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas

Latest News & Events

Nov 18, 2024

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Read More...

Nov 8, 2024

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read More...

Nov 6, 2024

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read More...